Glucosamine
The DOI matches its Crossref record.
Abstract
OBJECTIVE: To review the pharmacology and pharmacokinetics of glucosamine and critically evaluate currently available literature regarding its safety and efficacy. DATA SOURCE: A MEDLINE search was conducted between January 1965 and May 1997. Key words used in the search were osteoarthritis, osteoarthrosis, gonarthrosis, and glucosamine. In addition, references cited in articles obtained from the MEDLINE search were reviewed for additional literature. STUDY SELECTION AND DATA EXTRACTION: All articles were considered for inclusion in the review. Articles were excluded from critical evaluation for lack of randomization, lack of a control group, 30 or fewer study participants, inconsistent treatment regimen, incomplete dosing information, or incomplete reporting of results. DATA SYNTHESIS: Osteoarthritis affects approximately 12% of the US population; the incidence increases with increasing age. Currently used pharmacologic treatments, including acetaminophen and nonsteroidal antiinflammatory drugs, do not slow or reverse the degenerative process in osteoarthritis. Glucosamine has recently received a great deal of attention from the public as a potential treatment of osteoarthritis, prompting healthcare professionals to investigate its clinical usefulness and potential for adverse effects. The drug has been proposed to stop and possibly reverse the degenerative process in osteoarthritis. Following absorption of an oral dose, glucosamine is incorporated into plasma proteins during first-pass metabolism, resulting in 26% bioavailability. Unbound glucosamine is concentrated in the articular cartilage. Each of the three critically evaluated studies reported a decrease in the symptoms of osteoarthritis (e.g., decreased Lequesne index, decreased pain severity, increased range of motion) for the glucosamine group, which was greater than that obtained in the control group. Flaws in study design, however, prevent the use of these results in modifying current clinical practice. Reported short-term adverse effects include mild gastrointestinal problems, drowsiness, skin reactions, and headache. CONCLUSIONS: Improvement in the symptoms of osteoarthritis associated with the use of glucosamine has been observed in clinical trials; however, those trials have flaws in design and data analysis. Further research needs to be conducted before glucosamine can be recommended as a treatment for osteoarthritis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Glucosamine therapy for treating osteoarthritis
Towheed, T., Maxwell, L., Anastassiades, T. P., Shea, B., Houpt, J., Welch, V., Hochberg, M. C., & Wells, G. A. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002946.pub2 · Cited by 659
GLUT2 is a high affinity glucosamine transporter
Uldry, M., Ibberson, M., Hosokawa, M., & Thorens, B. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03058-2 · Cited by 338
Anderson, J. W., Nicolosi, R. J., & Borzelleca, J. F. (2005) · Food and Chemical Toxicology · doi:10.1016/j.fct.2004.11.006 · Cited by 311
When Food Becomes a Drug: Nonanabolic Nutritional Supplement Use in Athletes
Schwenk, T. L., & Costley, C. D. (2002) · The American Journal of Sports Medicine · doi:10.1177/03635465020300062701 · Cited by 106
The effect of glucosamine supplementation on people experiencing regular knee pain
Braham, R., Dawson, B., & Goodman, C. (2003) · British Journal of Sports Medicine · doi:10.1136/bjsm.37.1.45 · Cited by 89
Mechanick, J. I., Brett, E. M., Chausmer, A. B., Dickey, R. A., Wallach, S., Bergman, D. A., Garber, J. R., Hamilton, C. R., Handelsman, Y., Holdy, K. E., et al. (2003) · Endocrine Practice · doi:10.4158/ep.9.5.417 · Cited by 73
Metadata
- Authors
- Barclay, T. S., Tsourounis, C., & McCart, G. M.
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 1998-05
- Volume
- 32
- Issue
- 5
- Pages
- 574-579
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W4252912203
- Cited by
- 90
- References
- 0
- FWCI
- 4.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.